NasdaqGS:EXELBiotechs
Exelixis (EXEL) Valuation Check After CABINET Trial Data Fuels Renewed Growth Optimism
Exelixis (EXEL) is back in focus after new subgroup data from the phase 3 CABINET trial showed that CABOMETYX improved progression-free survival versus placebo in advanced neuroendocrine tumor patients across both non-functional and functional groups.
See our latest analysis for Exelixis.
The share price has moved to US$52.99 after a 26.92% 90 day share price return and a 24.62% 1 year total shareholder return, with momentum building alongside the CABINET data and recent conference and...